Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Dialysis

Biocompatible fluid for PD—hanging in the balANZ?

Nature Reviews Nephrology volume 8, page 252 (2012)Cite this article

Subjects

...the number of patients experiencing peritonitis was lower in the biocompatible group...

Results from the balANZ trial, which compared biocompatible and conventional fluid in patients on peritoneal dialysis, showed no difference in the rate of renal function decline between the groups over the 2-year follow-up. However, secondary outcomes such as time to anuria and time to peritonitis were significantly longer in the biocompatible group, which has important implications for clinical practice.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

ORIGINAL RESEARCH PAPER

  1. Johnson, D. W. et al. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J. Am. Soc. Nephrol. doi:10.1681/ASN.2011121201

Download references

Authors
  1. Helene Myrvang
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Myrvang, H. Biocompatible fluid for PD—hanging in the balANZ?. Nat Rev Nephrol 8, 252 (2012). https://doi.org/10.1038/nrneph.2012.49

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrneph.2012.49

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research